Nantilus
Cancer
Thephosphatidylinositol-3-kinase/proteinkinase(PI3K/PKB)signalingpa- way also known as the survival or anti-apoptotic pathway plays an - portant role in controlling cell growth, proliferation and survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in - man cancers an...
Enregistré dans:
| Auteur principal : | |
|---|---|
| Format : | Livre |
| Langue : | anglais |
| Titre complet : | Cancer / edited by Robert H. Bradbury. |
| Édition : | 1st ed. 2007. |
| Publié : |
Berlin, Heidelberg :
Springer Berlin Heidelberg
, [20..] Cham : Springer Nature |
| Collection : | Topics in medicinal chemistry (Berlin. Internet) ; 1 |
| Accès en ligne : |
Accès Nantes Université
Accès direct soit depuis les campus via le réseau ou le wifi eduroam soit à distance avec un compte @etu.univ-nantes.fr ou @univ-nantes.fr |
| Note sur l'URL : | Accès sur la plateforme de l'éditeur Accès sur la plateforme Istex |
| Condition d'utilisation et de reproduction : | Conditions particulières de réutilisation pour les bénéficiaires des licences nationales : https://www.licencesnationales.fr/springer-nature-ebooks-contrat-licence-ln-2017 |
| Contenu : | Overview. Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer. Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic. Survival Signaling. Progress in the Development of Agents to Control the Cell Cycle. HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit. Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy. Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy. Bcr-Abl Kinase Inhibitors |
| Sujets : | |
| Documents associés : | Autre format:
Cancer Autre format: Cancer Autre format: Cancer Autre format: Cancer |
| LEADER | 05206clm a2200709 4500 | ||
|---|---|---|---|
| 001 | PPN123132878 | ||
| 003 | http://www.sudoc.fr/123132878 | ||
| 005 | 20241002160200.0 | ||
| 010 | |a 978-3-540-33120-9 | ||
| 017 | 7 | 0 | |a 10.1007/978-3-540-33120-9 |2 DOI |
| 035 | |a (OCoLC)690283548 | ||
| 035 | |a Springer978-3-540-33120-9 | ||
| 035 | |a SPRINGER_EBOOKS_LN_PLURI_10.1007/978-3-540-33120-9 | ||
| 035 | |a Springer-11644-978-3-540-33120-9 | ||
| 100 | |a 20080410f20 u y0frey0103 ba | ||
| 101 | 0 | |a eng |2 639-2 | |
| 102 | |a DE | ||
| 135 | |a dr||||||||||| | ||
| 181 | |6 z01 |c txt |2 rdacontent | ||
| 181 | 1 | |6 z01 |a i# |b xxxe## | |
| 182 | |6 z01 |c c |2 rdamedia | ||
| 182 | 1 | |6 z01 |a b | |
| 183 | |6 z01 |a ceb |2 RDAfrCarrier | ||
| 200 | 1 | |a Cancer |f edited by Robert H. Bradbury. | |
| 205 | |a 1st ed. 2007. | ||
| 214 | 0 | |a Berlin, Heidelberg |c Springer Berlin Heidelberg | |
| 214 | 2 | |a Cham |c Springer Nature |d [20..] | |
| 225 | 0 | |a Topics in Medicinal Chemistry |x 1862-247X |v 1 | |
| 327 | 1 | |a Overview |a Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer |a Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK |a Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic |a Survival Signaling |a Progress in the Development of Agents to Control the Cell Cycle |a HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit |a Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy |a Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy |a Bcr-Abl Kinase Inhibitors | |
| 330 | |a Thephosphatidylinositol-3-kinase/proteinkinase(PI3K/PKB)signalingpa- way also known as the survival or anti-apoptotic pathway plays an - portant role in controlling cell growth, proliferation and survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in - man cancers and its potential biological effects (e. g. , competitive growth advantage, evasion from apoptosis and therapy resistance) has suggested the potential use of PI3K/PKB pathway modulators as novel targeted therapeutic agents. Following this strategy, a number of compounds have demonstrated antitumor activity in preclinical and clinical settings by targeting directly or indirectly the different components of this pathway. This work covers - cent salient medicinal chemistry achievements in the identi?cation of these pathway modulators, updating recent reports on this class of potential c- cer drugs [1 4]. To help the reader, each section of this piece of work starts with a brief background to understand the target rationale and then moves on to the lead discovery, drug optimization, and clinical results stages as - propriate. A schematic representation of signaling through this pathway and the pathway components covered herein are shown in Fig. 1. Fig. 1 Schematic representation of signaling through the PI3K/PKB pathway 172 C. Garcia-Echeverria 2 Insulin-likeGrowthFactorI Receptor The Insulin-like Growth Factor-I Receptor (IGF-IR) is a member of the - sulin receptor family of tyrosinekinases. This transmembrane-spanning p- tein is composed of two ?-andtwo ?-subunits linked by disul?de bonds | ||
| 371 | 0 | |a Accès en ligne pour les établissements français bénéficiaires des licences nationales | |
| 371 | 0 | |a Accès soumis à abonnement pour tout autre établissement | |
| 371 | 1 | |a Conditions particulières de réutilisation pour les bénéficiaires des licences nationales |c https://www.licencesnationales.fr/springer-nature-ebooks-contrat-licence-ln-2017 | |
| 410 | | | |0 125028539 |t Topics in medicinal chemistry (Berlin. Internet) |x 1862-247X |v 1 | |
| 452 | | | |t Cancer |b Texte imprimé |y 9783540331193 | |
| 452 | | | |t Cancer |b Texte imprimé |y 9783540822011 | |
| 452 | | | |t Cancer |b Texte imprimé |y 9783642069666 | |
| 452 | | | |t Cancer |b Texte imprimé |y 9783540331193 | |
| 517 | | | |a With contributions by numerous experts | |
| 610 | 1 | |a Chemistry | |
| 610 | 2 | |a Medicinal Chemistry | |
| 610 | 2 | |a Pharmacology/Toxicology | |
| 610 | 2 | |a Organic Chemistry | |
| 610 | 2 | |a Molecular Medicine | |
| 615 | |a @Chemistry and Materials Science |n 11644; ZDB-2-CMS |2 Springer | ||
| 615 | |a @Chemistry and Materials Science |n 11644 |2 Springer | ||
| 615 | |a Chemistry and Materials Science |n 11644 |2 Springer | ||
| 676 | |a 615.19 |v 23 | ||
| 680 | |a RS400-431 | ||
| 700 | 1 | |a Bradbury |b Robert H. |4 070 | |
| 702 | 1 | |a Bradbury |b Robert H. |4 340 | |
| 801 | 3 | |a FR |b Abes |c 20240911 |g AFNOR | |
| 801 | 1 | |a DE |b Springer |c 20211104 |g AACR2 | |
| 856 | 4 | |q PDF |u https://doi.org/10.1007/978-3-540-33120-9 |z Accès sur la plateforme de l'éditeur | |
| 856 | 4 | |u https://revue-sommaire.istex.fr/ark:/67375/8Q1-8D1K08BV-W |z Accès sur la plateforme Istex | |
| 856 | 4 | |5 441099901:830930140 |u https://budistant.univ-nantes.fr/login?url=https://doi.org/10.1007/978-3-540-33120-9 | |
| 915 | |5 441099901:830930140 |b SPRING4-00355 | ||
| 930 | |5 441099901:830930140 |b 441099901 |j g | ||
| 979 | |a NUM | ||
| 991 | |5 441099901:830930140 |a Exemplaire créé en masse par ITEM le 01-10-2024 15:47 | ||
| 997 | |a NUM |b SPRING4-00355 |d NUMpivo |e EM |s d | ||
| 998 | |a 980268 | ||